.png)
How Duritect™ works
Duritect™ combines a simple blood test with advanced machine learning technology to assess a patient’s risk of having Alzheimer’s disease (AD) or Parkinson’s disease (PD), quickly and reliably.1,2
It utilizes the immune system’s unique yet consistent reaction to the presence of disease pathology by identifying specific autoantibodies in the blood as biomarkers of AD or PD.3-5
Learn more on this page
- How Duritect™ works
- Why use autoantibodies as biomarkers?
- The test workflow
- Research publications
A blood-based autoantibody test
Utilizing a patient’s immune system to determine their risk of having AD or PD3,6-8
Thousands of autoantibodies are involved in the clearance of debris within the body
The presence of disease leads to excessive debris from the affected organ(s)
Excessive debris in the blood leads to changes in autoantibody levels to clear the debris
The differences in autoantibody levels serve as effective biomarkers for the disease
Multi-analyte approach
Assesses a distinct panel of multiple autoantibodies to indicate the possible presence of disease pathology
Machine learning algorithm
Ensures a robust, unbiased approach to disease risk assessment through rigorous statistical analysis
Why use autoantibodies as biomarkers?
Research has shown that blood-based autoantibodies are effective biomarkers for disease.4
Early indicators
of disease
Autoantibody levels in the blood can change in response to disease pathology before other significant changes happen.3
High sensitivity
and specificity
Autoantibodies have shown high accuracy, sensitivity, and specificity in distinguishing AD or PD from healthy states and other diseases.3-5,9,10
Subtype and
stage detection
Autoantibodies could also be useful for differentiating between various stages of diseases, facilitating staging and monitoring.3,11
Stability in
the blood
Autoantibodies are reliable markers for testing at any given time,3 without needing any preparation before or after collection.
Efficiency
and accuracy
Combining a multi-analyte analysis approach with machine learning improves efficiency and accuracy.3
Minimally invasive and
cost-effective
Blood tests are minimally invasive and affordable, making them accessible in a wide range of healthcare settings.3
The test workflow
Duritect™ measures serum levels of autoantibody biomarkers using protein antigen targets attached to magnetic beads. The tests run on a trusted and widely used technology for high-throughput analysis of biomolecules, including autoantibodies.1-3
Serum
sample collected
sample collected
The process starts with a simple blood draw in the primary care setting.
Sample sent
to laboratory
to laboratory
The serum sample is delivered to our CLIA/CAP laboratory* for clinical analysis.
Sample analyzed
by laboratory
by laboratory
The serum sample is analyzed by our experts in the lab and resulting data is entered into our ML-algorithm for the risk score prediction.
Sample report
generated
generated
The sample risk score is entered into the final physician & patient reports and signed by medical directors for accuracy.
Sample report
delivered
delivered
Signed final reports are delivered to the ordering physician and patient to conclude the analysis.